Kevin Emery Boczar, Sheojung Shin, Robert A deKemp, Dar Dowlatshahi, Anahita Tavoosi, Christiane Wiefels, Peter Liu, Heather Lochnan, Paul A MacPherson, Aun Yeong Chong, Carlos Torres, Eugene Leung, Ahmed Tawakol, Ali Ahmadi, Linda Garrard, Chantal Lefebvre, Cathy Kelly, Poppy MacPhee, Everad Tilokee, Paolo Raggi, George A Wells, Rob Beanlands
BACKGROUND: Inflammation is a key mediator in the development and progression of the atherosclerotic disease process as well as its resultant complications, like myocardial infarction (MI), stroke and cardiovascular (CV) death, and is emerging as a novel treatment target. Trials involving anti-inflammatory medications have demonstrated outcome benefit in patients with known CV disease. In this regard, colchicine appears to hold great promise. However, there are potential drawbacks to colchicine use, as some studies have identified an increased risk of infection, and a non-significant trend for increased all-cause mortality...
November 10, 2023: BMJ Open